Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients

Thrombosis Research

Volumn 120, Issue 6, 2007, Pages 871-876

  Pawlak, Krystyna ^a   Pawlak, Dariusz ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Cardiovascular disease; Coagulation; Hemodialysis; Urokinase type plasminogen activator system

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTHROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LOGISTIC REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; LOGISTIC MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTHROMBIN; RENAL DIALYSIS; SUPEROXIDE DISMUTASE; THROMBOPLASTIN; URINARY PLASMINOGEN ACTIVATOR;

EID: 34548685872     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.01.011     Document Type: Article

References (34)

1. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) S112-S119
2. Zoccali C. Cardiovascular risk in uraemic patients - is it fully explained by classical risk factors?. Nephrol Dial Transplant 15 (2000) 454-457
3. Inoue A., Wada H., Takai M., Yamamuro M., Mukai K., Nakasaki T., et al. Haemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb/Haemost 6 (2000) 100-103
4. Tomura S., Nakamura Y., Mayumi D., Ando R., Ida T., Chida Y., et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipids as a cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 27 (1996) 848-854
5. Boaz M., Matas Z., Biro A., Katzir Z., Green M., Fainauru M., et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 34 (1999) 438-444
6. Himmelfarb J., Stenvinkel P., Ikizler T.A., and Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 (2002) 1524-1538
7. Toschi V., Gallo R., Lettino M., Fallon J.T., Gertz S.D., Fernandez-Ortiz A., et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95 (1997) 594-599
8. Rosenberg R.D., and Bauer K.A. Prothrombin activation fragment assay. Clin Chem 39 (1993) 559-560
9. Raghunath P.N., Tomaszewski J.E., Brady S.T., Caron R.J., Ocada S.S., and Barnathan E.S. Plasminogen activator system in human coronary atherosclerosis. Atheroscler Thromb Vasc Biol 15 (1995) 1432-1443
10. Pawlak K., Borawski J., Naumnik B., and Myśliwiec M. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res 109 (2003) 247-251
11. Pawlak K., Naumnik B., Brzósko S., Pawlak D., and Myśliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 24 (2004) 154-161
12. Pawlak K., Pawlak D., and Mysliwiec M. Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thromb Res 117 (2006) 517-522
13. Haddock R.C., Spell M.L., Baker III C.D., Grammer J.R., Parks J.M., Speidel M., et al. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem 266 (1991) 21446-21473
14. Reuning U., and Bang N.U. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. Arterioscler Thromb 12 (1992) 1161-1170
15. Nykjaer A., Petersen C.M., Christensen E.I., Davisen O., and Gliemann J. Urokinase receptors in human monocytes. Biochim Biophys Acta 1052 (1990) 399-407
16. Kaikita K., Takeya M., Ogawa H., Suefuji H., Yasue H., and Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 188 (1999) 180-188
17. Soejima H., Ogawa H., Yasue H., Kaikita K., Nishiyama K., Misumi K., et al. Hightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99 (1999) 2908-2913
18. Borawski J., Naumnik B., and Mysliwiec M. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease and erythropoietin therapy. Clin Appl Thrombosis/Hemostasis 8 (2002) 359-367
19. Tremoli E., Camera M., Tosch V., and Colli S. Tissue factor in atherosclerosis. Atherosclerosis 144 (1999) 273-283
20. Fiorucci S., Mencarelli A., Meneguzzi A., Lechi A., Morelli A., del Soldato P., et al. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation 106 (2002) 3120-3125
21. Taniguhi T., Kakkar A.K., Tuddenham E.G., Williamson R.C., and Lemoine N.R. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 58 (1998) 4461-4467
22. Marcucci R., Prisco D., Brunelli T., Pepe G., Gori A.M., Fedi S., et al. Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thromb Haemost 83 (2000) 826-832
23. Kim H.K., Song K.S., Park Y.S., Yun Y.S., and Shim W.H. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology 93 (2000) 31-36
24. Saigo M., Abe S., Ogawa M., Yamashita T., Biro S., Minagoe S., et al. Imbalance of plasminogen activator inhibitor-1/tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 86 (2001) 1197-1203
25. Krasnikowa T.L., Parfyonova Ye.V., Alekseeva I.A., Arefieva T.I., Mukhina S.A., et al. Urokinase plasminogen activator system in humans with stable coronary artery disease. Clin Experim Pharmacol Physiol 26 (1999) 354-357
26. May A.E., Schmidt R., Kanase S.M., Chavakis T., Stephens R.W., Schomig A., et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 100 (2002) 3611-3617
27. Steins M.B., Padro T., Schwaenen C., Ruiz S., Mesters R.M., Berdel W.E., et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 15 (2004) 383-391
28. Chavakis T., Kanse S.M., Yutzy B., Lijnen H.R., and Preissner K.T. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complex. Blood 91 (1998) 2305-2312
29. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., et al. Regulation of integrin function by urokinase receptor. Science 273 (1996) 1551-1555
30. Chavakis T., May A.E., Preissner K.T., and Kanse S.M. Molecular mechanisms of zink-dependent leukocyte adhesion involving the urokinase receptor and β2-Integrins. Blood 93 (1999) 2976-2983
31. Pepper M.S., Sappino A.P., Stocklin R., Orci L., and Vassalli J.D. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 122 (1993) 673-684
32. Kanse S.M., Benzakour O., Kanthou C., Kost C., Lijnen H.R., and Preissner K.T. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 17 (1997) 2848-2854
33. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., and Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16 (1997) 7279-7286
34. Mondino A., and Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 25 (2004) 450-455